Funding

We are currently supported by:

• Alzheimer's Research UK (ARUK)

Pilot grant to T.A.S. and Rachel: "Modeling C9ORF72 DPR pathology using optogenetic approaches for mechanistic ALS/FTD research and drug discovery" (2024-2026) (funds Sabin)

• UKRI

Future Leaders Fellowship to T.A.S. "RNP complexes in health and disease and their therapeutic targeting" (2022-2026)

• Motor Neurone Disease Association

PhD studentship: "NEAT1 isoforms in the regulation of cellular glucose metabolism downstream TDP-43 dysfunction in ALS" (2023-2027) (funds Ruaridh)

• MRC

Research grant: "Mechanistic studies of ALS-causative mutations and RNP-focussed drug discovery using in vitro reconstitution of RNP complexes" (2022-2025)

• MND Scotland

PhD Studentship: "Small molecule modulators of stathmin-2 splicing as a novel ALS therapy" (2022-2025) (funds Brittany)

• BBSRC

Research grant: “Understanding the crosstalk between spatially separated RNP granules during cellular stress responses” (2022-2024)

• MRC/AZ Centre for Lead Discovery award for the identification of small molecules modulators of NEAT1_2/paraspeckles (co-I, with Cardiff)

Past funding:

• MND Association Senior Non-Clinical Fellowship “Long non-coding RNA NEAT1 in motor neurone physiology and pathophysiology” (2018-2024)
• Medical Research Foundation fellowship “Dissecting the role of the paraspeckle in amyotrophic lateral sclerosis” (2015-2018)
• Academy of Medical Sciences Springboard Award: “Developing tools to monitor expression of lncRNA NEAT1 isoforms for basic research and drug discovery” (2019-2021)
• ISSF Wellcome Trust Translational Kickstart Award “Identification of chemotypes selectively binding to a structured motif of lncRNA NEAT1 as templates for novel drugs” (2019-2021)
• Welsh Government Sêr Cymru III – Tackling COVID-19 grant (2020-2021)